Press Release

Carl Zeiss Vision International GmbH announces agreement to acquire Brighten Optix

4 June 2025

Aalen, Germany | 4 June 2025 | ZEISS Vision Care

This acquisition will enhance the company’s portfolio of myopia management solutions and further reinforce its leading global position in vision care by also integrating specialty contact lenses.

Carl Zeiss Vision International GmbH announced today that it has entered a definitive agreement to acquire 100% of the shares in Brighten Optix, listed on Taipei Exchange. Brighten Optix is a leading player in the field of orthokeratology (short: ortho-k)* and specialty contact lenses. The capability and products of Brighten Optix will now play an important role in ZEISS Vision Care’s long-term strategy and success. With this acquisition, ZEISS Vision Care is making a strong addition to its already successful myopia management portfolio.

Brighten Optix products are already widely available and successfully used by eye care professionals and eye clinics in Greater China and across Southeast Asia. Their proven and innovative portfolio of specialty contact lenses will complement ZEISS Vision Care’s existing myopia control offerings. Ortho-k lenses are used to manage progressive myopia in children; a condition which can lead to high myopia and even loss of sight. Brighten Optix offers some of the market’s most advanced products and brands such as myOK.

“Progressive myopia is one of the biggest vision care challenges we see in the world today. The topic is so important as the sight of children is at risk. We are already proud of our spectacle lens portfolio, which is clinically proven to significantly slow the progression of myopia. But at the same time, we also know that we need to offer even more options to our partners, the doctors and eye care professionals. That is why we are delighted to have found such a great partner. Our future partnership will allow us to meet exactly this need. We will broaden our portfolio and enable our customers to protect and improve the vision of many more children”, says Sven Hermann, CEO of ZEISS Vision Care and Member of the Executive Board of ZEISS. “Furthermore, Brighten Optix is known for its commitment to research and development. With ZEISS’ heritage of leading innovation, I am confident that this common strength will be of even greater advantage in our joint future”, Hermann concludes.

“We are excited to join a leading, worldwide and visionary company like ZEISS,” says Richard Wu, General Manager of Brighten Optix. “Our business has flourished thanks to pioneering, industry-leading products, and we're eager to capitalize on this chance to help grow and shape the future of vision care and in particular contact lenses and myopia management. Personally, I am proud and thankful to everyone at Brighten Optix for their unwavering commitment and expertise in improving and protecting vision over the last 50 years since my father founded the company. And I am confident that the talented teams of Brighten Optix and ZEISS Vision Care will accomplish great things together”, Wu adds.

The acquisition is expected to close early 2026. The transaction remains subject to completion of certain conditions and all applicable regulatory approvals. Morgan Stanley served as exclusive financial advisor to ZEISS Vision Care in relation to this transaction.


*Orthokeratology in short Ortho-K: The patient wears form-stable contact lenses at night to change the curvature of the cornea, so the wearer can see well without glasses during the day. These lenses have been shown to reduce the progression of myopia.

Portrait Maria Conrad
Press Contact Maria Conrad General Topics and Sustainability

ZEISS Vision Care

About ZEISS

ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totaling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (updated: 30 September 2024).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. ZEISS' significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.

With more than 46,555 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025). The headquarters of the company, which was founded in Jena in 1846, is located in Oberkochen, Germany. The Carl Zeiss Foundation, one of Germany’s largest foundations committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

 

ZEISS Vision Care
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.

 

About Brighten Optix
Brighten Optix is the leading manufacturer of rigid contact lenses in Taiwan, seamlessly integrating expertise in research and development, manufacturing, and clinical applications. With nearly 50 years dedicated to holistic vision care, the company is committed to providing innovative solutions that empower people to achieve clearer, better vision.
As a Class III medical device manufacturer, Brighten Optix is the only Taiwanese company with three approved orthokeratology lens licenses in mainland China. The company distributes corrective lenses across Taiwan and mainland China, and is actively expanding its global footprint to meet the growing demand for advanced vision correction solutions worldwide.
For more information, please visit: http://www.brightenoptix.com


Share this article